S. 3087: Stop Pills That Kill Act
The "Stop Pills That Kill Act" aims to strengthen regulations and enforcement against counterfeit substances containing fentanyl and methamphetamine. Here are the key components of the bill:
Definitions
The bill specifically defines what constitutes a "counterfeit fentanyl or methamphetamine substance." This includes any substance that:
- Contains fentanyl, its analogues, or methamphetamine.
- Is marketed, sold, or falsely labeled under the trademark or name of another product.
Prohibited Acts
The bill amends existing law (the Controlled Substances Act) to explicitly prohibit certain activities related to counterfeit substances, making it illegal to engage in these activities involving fentanyl and methamphetamine.
Comprehensive Plan
The bill requires the Administrator of the Drug Enforcement Administration (DEA) to develop a comprehensive operation and response plan within 180 days of the bill's enactment. This plan should include:
- Strategies to enhance federal law enforcement's ability to investigate and seize counterfeit substances.
- Increased education and prevention efforts aimed at stopping the use of these dangerous counterfeit drugs, particularly targeting youth and teens.
- A review of existing campaigns like "One Pill Can Kill" to assess and improve their effectiveness in combating counterfeit drug use.
Reporting to Congress
The bill mandates that the Attorney General, in consultation with DEA and the Office of National Drug Control Policy, submits an annual report to Congress. This report should include:
- Data on the number of counterfeit substances seized by federal law enforcement.
- A breakdown of how many of these counterfeit substances were in pill form.
- Information on the other illicit substances found in counterfeit pills.
- Details regarding when and where these counterfeit substances were seized.
- Information about charges filed against individuals involved in the manufacturing or distribution of these counterfeit substances.
- Data on convictions and sentences related to these crimes.
- Updates on prevention measures and public awareness campaigns being undertaken by federal agencies.
Implementation
The bill emphasizes timely implementation of its provisions in hopes of effectively addressing the ongoing issue of counterfeit fentanyl and methamphetamine substances.
Relevant Companies
- ABT - Abbott Laboratories could be affected if there are regulatory changes in drug manufacturing practices due to the increased scrutiny on counterfeit products.
- PFE - Pfizer Inc. might face impacts related to enforcement actions against counterfeit medications that could involve their products.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
3 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Oct. 30, 2025 | Introduced in Senate |
| Oct. 30, 2025 | Read twice and referred to the Committee on the Judiciary. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
